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a  b  s  t  r  a  c  t
Objective: To investigate the feasibility of bone turnover markers for the assessment of bone
metabolism in patients with systemic lupus erythematosus, according to the guidelines
of  the International Osteoporosis Foundation and the International Federation of Clinical
Chemistry and Laboratory Medicine.
Methods: The study included 43 female systemic lupus erythematosus patients. Serum
procollagen type I N propeptide, C-terminal telopeptide of type I collagen, osteocalcin,
parathyroid hormone, 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, anti-cardiolipin,
anti-dsDNA, and anti-nucleosome levels were measured.
Results: Procollagen type I N propeptide and C-terminal telopeptide of type I collagen levels
were elevated in systemic lupus erythematosus patients aged >45 in comparison to those
aged <45, although with borderline signiﬁcance (p = 0.05, respectively). Correlations were
found between bone turnover markers: the strongest being between procollagen type I N
propeptide and osteocalcin ( = 0.69, p < 0.05). Procollagen type I N propeptide and osteocalcin
were found to be associated with parathyroid hormone ( = 0.3,  = 0.29, respectively, p < 0.05).
Age  correlated with procollagen type I N propeptide ( = 0.23, p < 0.05). Elevated procollagen
type  I N propeptide was found more frequently than elevated osteocalcin or C-terminal
telopeptide of type I collagen, both in patients aged <45 (p = 0.001) and >45 (p < 0.001). No sig-niﬁcant difference in procollagen type I N propeptide, osteocalcin or C-terminal telopeptide
of  type I collagen levels was found with respect to season, neither in the entire systemic
lupus erythematosus group nor in the under-45 or over-45 groups. Previous glucocorticoid
treatment was not associated with difference in bone turnover markers.
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Conclusions: Increased bone turnover markers in systemic lupus erythematosus appear to
predominantly reﬂect the pattern of bone remodeling related to age. Increased procollagen
type I N propeptide is expected to be the most frequent outcome among bone turnover
markers. Better diagnoses of bone disturbances with bone turnover markers performed in
accordance with international reference standards need to be included in the approach to
systemic lupus erythematosus patients, in addition to bone mineral density assessment.
©  2014 Elsevier Editora Ltda. All rights reserved.
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r  e  s  u  m  o
Objetivo: Investigar a viabilidade dos marcadores de remodelac¸ão óssea (MRO)  na avaliac¸ão
do  metabolismo ósseo em pacientes com lúpus eritematoso sistêmico (LES), de acordo com
as  diretrizes da International Osteoporosis Foundation e da International Federation of
Clinical Chemistry and Laboratory Medicine.
Métodos: O estudo incluiu 43 pacientes do sexo feminino com LES. Foram medidos os níveis
séricos de propeptídeo N-terminal do procolágeno tipo I (PINP), telopeptídeo C-terminal do
colágeno tipo I (CTX), osteocalcina, HPT, 25(OH)D, anticorpos anticardiolipina, antidsDNA e
antinucleossomo.
Resultados: Os níveis de PINP e CTX estavam elevados em pacientes com LES com idade
>45,  em comparac¸ão com aqueles com idade <45 anos, embora com signiﬁcância estatís-
tica  limítrofe (p = 0,05). Foram encontradas correlac¸ões entre os MRO: a mais forte foi entre
o  PINP e a osteocalcina ( = 0,69, p < 0,05). Encontrou-se que o PINP e a osteocalcina estão
correlacionados com o HPT ( = 0,3,  = 0,29, respectivamente, p < 0,05). A idade estava cor-
relacionada com o PINP ( = 0,23, p < 0,05). Valores elevados de PINP foram encontrados em
maior frequência do que valores elevados de osteocalcina ou CTX, tanto em pacientes com
idade  <45 (p = 0,001) quanto >45 (p < 0,001). Não houve diferenc¸a estatisticamente signiﬁca-
tiva nos níveis de PINP, osteocalcina ou CTX com relac¸ão à estac¸ão do ano, nem em todo o
grupo de pacientes com LES, nem naqueles com mais ou menos de 45 anos. O uso prévio
de  glucocorticoides não esteve associado a diferenc¸as nos MRO.
Conclusões: O aumento nos MRO no LES parece reﬂetir predominantemente o padrão de
remodelac¸ão  óssea relacionado com a idade. Pode-se esperar que o PINP aumentado seja o
desfecho mais comumente encontrado entre os MRO. É necessário incluir melhores diag-
nósticos de distúrbios ósseos com MRO, feitos de acordo com as normas internacionais de
referência, na abordagem de pacientes com LES, além de avaliar a densidade mineral óssea.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
In 2011, the International Osteoporosis Foundation (IOF) and
the International Federation of Clinical Chemistry and Lab-
oratory Medicine (IFCC) stated that assessment of a marker
of bone formation, serum procollagen type I N propeptide
(PINP), and a marker of bone resorption, serum C-terminal
telopeptide of type I collagen (CTX), provided reference param-
eters for bone turnover markers (BTMs) in clinical studies.1
Increased serum concentration of BTMs may predict fracture
risk in postmenopausal women, independent of bone mineral
density (BMD) measurements.1 High bone turnover may be
associated not only with bone loss, resulting in a low BMD, but
also with the deterioration of bone architecture not detected
in bone mass assessment.1 Bone strength is determined by
both BMD  and bone quality.2 Apart from BMD, bone quality
depends mainly on micro-architecture and bone turnover.2Osteoporosis, and consequently indication for treatment, is
diagnosed either clinically on the basis of fractures following
low energy trauma, or in the pre-fracture stage by assessment
of clinical risk factors associated with densitometry and bone
metabolism.3
In a recent study of Mak et al. conducted on 45 patients
with systemic lupus erythematosus (SLE), a high 10-year
fracture risk was found in 16% of patients and in 2% of
healthy controls.4 Demonstration of a high (>20%) individ-
ual 10-year absolute fracture risk is the criterion for initiation
of pharmacological treatment.3 As pregnancy is an absolute
contraindication to dual X-ray absorptiometry (DXA) in the
assessment of BMD,  and female SLE patients of child-bearing
age may be apprehensive of densitometry, compliance might
be limited. Under such circumstances, BTM analysis would
appear to be a practical alternative, as samples of blood are
easily collected and the procedure is relatively noninvasive.1
BTMs have been used in clinical researches for many  years,






















































ar e v b r a s r e u m a t o l
ut there is still a need for stronger evidence on their usage in
LE.
Due to the sparse evidence addressing PINP and CTX
n lupus patients, the aim of the study was to investi-
ate BTMs, including those recommended by IOF–IFCC, and
o assess their feasibility as clinical markers in patients
ith SLE in remission. To our knowledge, this is the ﬁrst
tudy concerning the simultaneous assessment of PINP and
TX, in female patients with SLE. As no data regarding
he newer biochemical parameters of bone metabolism has
o far been published, osteocalcin (OC), parathyroid hor-
one (PTH) and vitamin D levels are also investigated. Since
traumatic metatarsal stress fractures have been reported to
ccur in SLE, particularly in association with the antiphos-
holipid syndrome, anti-cardiolipin (aCL) antibodies are also
nvestigated.5
aterials  and  methods
he study included a limited number of 43 female patients
ith SLE, aged 27–75 (mean 46.09 ± 12.87). The diagnosis of
LE was based on the classiﬁcation criteria for SLE updated in
997 by the American College of Rheumatology.6 The dura-
ion of SLE ranged from 2 to 24 years (mean 10.32 ± 5.47
ears). At the time of the study, the entire group of SLE
atients were found to have a disease activity <6, as indi-
ated by SLEDAI.7 Exclusion criteria for the SLE patients in
his study were pregnancy; the presence of disease known
o affect bone turnover not related to SLE, such as chronic
enal failure, chronic liver disease, inﬂammatory bowel dis-
ase, hyperparathyroidism, hypogonadism; any medication
nown to affect bone turnover with the exception of cal-
ium or vitamin D supplements; glucocorticoids or the drugs
sed for the treatment of SLE. Any treatment with pred-
isolone or equivalent, ≥5 mg/day in the preceding 6 months,
as recorded. The study was approved by the local Ethics
ommittee.
The studied individuals were inhabitants of the Lodz
egion, which is located between the 51◦ and 52◦ northern
atitudes. The solar spectrum in absolute units of the area
easured on June 30, 2010, 10.47 GMT  is given in detail
lsewhere.8 As the study population was located in the north-
rn hemisphere, the seasonal variation of vitamin D status
as determined thus: the cold season was deﬁned as the
eriod between November and April while the warm one
ncluded the remaining months.
Serum was collected in the morning and stored at −70 ◦C
ntil assayed. PINP, N-MID Osteocalcin, B-Cross Laps (CTX),
TH and 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
25(OH)D) were measured with reagents, including calibration
nd control sera, obtained from Roche Diagnostic, Mannheim,
ermany. Electrochemiluminescence immunoassay (ECLIA)
as performed using an Elecsys 2010 automated analyzer.
or the evaluation of bone formation, PINP and serum OC
oncentrations were measured automatically using chemi-
uminescence immunoassays (Elecsys; Roche Diagnostics).
ccording to the manufacturer’s guidelines, the normal range
f serum concentration of PINP is <30 ng/mL in individuals
ged <45, and <37 ng/mL in those aged >45. The normal range 5;5 5(2):133–139 135
of serum concentration of OC is <31 ng/mL in subjects aged
<45, and <41 ng/mL in those aged >45.
For the evaluation of bone resorption, the concentration
of serum CTX was assayed automatically using chemi-
luminescence immunoassay. The normal range of serum
concentration of CTX is known to be <0.3 ng/mL at age <45, and
<0.6 ng/mL at age >45. PTH (pg/mL) was measured in a routine
procedure. Serum 25(OH)D concentrations were determined
by immunochemiluminescence (Elecsys, Roche Diagnostics),
controlled and certiﬁed by The International Vitamin D Pro-
ﬁciency – Testing Program (DEQAS). Vitamin D status was
deﬁned as follows: deﬁciency <20 ng/mL (<50 nmol/L), insufﬁ-
ciency 20–29 ng/mL (50–72.5 nmol/L) and recommended range
30–80 ng/mL (72.5–200 nmol/L).9
Autostat II ACA IgM and IgG kits were used to detect aCL
antibodies (Hycor, USA), while ELISA QUANTA Lite® dsDNAkit
(INOVA, USA) and Nucleosome IgG ELISA kit (D-tek, Belgium)
were used for assessment of anti-dsDNA and anti-nucleosome
(aNuc) antibodies, respectively. The levels of anti-dsDNA, aNuc
and aCL antibodies were variables in the assessment of lupus
activity.
Statistical analysis was performed using Statistica soft-
ware version 10.0 (Statsoft, Poland). As the distribution of
the measured variables was not Gaussian, according to
the Shapiro–Wilk test, the nonparametric tests were used.
Mann–Whitney U test was employed to compare variables
between two independent groups. The Kendall tau rank corre-
lation coefﬁcient was used to estimate correlation and validity,
and the Cochran’s Q test was employed to estimate the reli-
ability of the results. The Fisher’s exact test was used in the
assessment of the signiﬁcance of the association between cat-
egorical data, i.e. results of BTMs out of the reference range,
according to age, and other studied parameters, i.e. renal
involvement, menopause, any treatment with prednisolone
or equivalent, ≥5 mg/day in the preceding 6 months, and vita-
min  D deﬁciency. In descriptive statistics means and standard
deviations were used. In all calculations, p < 0.05 was regarded
as statistically signiﬁcant.
Results
Comparison of BTMs, PTH, 25(OH)D, aCL, anti-DNA and aNuc
antibodies obtained in patients with SLE according to age <45
and >45 are shown in Table 1.
PINP and CTX levels were elevated in SLE patients aged >45
in comparison to those at the age <45, however, only with bor-
derline signiﬁcance (42.4 ± 43.8 vs. 48.8 ± 29.1 ng/mL; 0.2 ± 0.1
vs. 0.3 ± 0.2 ng/mL; p = 0.05, respectively).
In SLE, all BTMs were signiﬁcantly positively correlated one
with another, with the strongest correlation being between
PINP and OC (p < 0.05) (Table 2).
PINP and OC were also correlated with PTH (p < 0.05). Age
was correlated with PINP. Anti-dsDNA level was correlated
with aNuc and aCL IgG antibodies (p < 0.05).
In a subgroup of SLE patients aged <45, 3 (14.28%)
patients had a CTX level elevated above the recommended
range (>0.3 ng/mL); one patient (4.76%) displayed an ele-
vated OC level (>31 ng/mL), and 9 (42.85%) patients displayed
an increased PINP concentration (>30 ng/mL). No association
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Table 1 – Procollagen type I N propeptide (PINP), osteocalcin (OC), C-terminal telopeptide of type I collagen (CTX),
parathyroid hormone (PTH), 25(OH)D, anti-cardiolipin (aCL), anti-dsDNA and anti-nucleosome (aNuc) antibodies in




>45  years old
N = 22
PINP [ng/mL] 42.4 ± 43.8 48.8 ± 29.1 0.05a
OC [ng/mL] 14.8 ± 9.3 19.2 ± 13.3 0.16
CTX [ng/mL] 0.2 ± 0.1 0.3 ± 0.2 0.05a
PTH [pg/mL] 37.5 ± 20.2 45.6 ± 26.8 0.23
25(OH)D [ng/mL] 27.3 ± 7.0 31.0 ± 11.6 0.29
aCL IgM [U/mL] 16.0 ± 13.6 10.1 ± 11.9 0.08
aCL IgG [U/mL] 24.2 ± 24.1 21.6 ± 19.0 0.94
Anti-dsDNA [IU/mL] 311.9 ± 397.0 315.0 ± 382.9 0.77
Anti-Nuc [U/mL] 1.2 ± 1.4 0.9 ± 0.9 0.81
SLE duration [years] 8.4 ± 5.4 12.3 ± 4.9 0.02a Mann–Whitney U test.
was found between results of BTMs out of the reference
range, according to age, and renal involvement (2/21; 9.52%),
menopause (0; 0%), any treatment with prednisolone or equiv-
alent, ≥5 mg/day in the preceding 6 months (13/21; 61.9%) and
vitamin D deﬁciency (2/21; 9.52%) in a subgroup of SLE patients
aged <45.
In the subgroup of SLE patients aged >45, 3 (13.63%) patients
were found to have an increased CTX level (>0.6 ng/mL); one
patient (4.54%) had an elevated OC level (>41 ng/mL), and
13 (59.09%) patients had an increased PINP concentration
(>0.6 ng/mL). No association was found between results of
BTMs out of the reference range, according to age, and renal
involvement (2/22; 9.09%), menopause (16/22; 72.72%), any
treatment with prednisolone or equivalent, ≥5 mg/day in the
preceding 6 months (13/22; 59.09%) and vitamin D deﬁciency
(2/22; 9.09%) in a subgroup of SLE patients aged >45.
According to an analysis of the differences between the
frequencies of elevated results, i.e. between those inside and
those outside the normal range by the Cochran’s Q test,
increases in PINP were signiﬁcantly more  common than ele-
vations in OC and CTX in all subjects: both those aged <45
Table 2 – Correlations of bone turnover markers, PTH, 25(OH)D,
with SLE.
Variable PINP OC CTX PTH 25(OH)D aCL 
PINP – 0.69a 0.50a 0.30a 0.04 0.1
OC 0.69a – 0.48a 0.29a −0.01 0.0
CTX 0.50a 0.48a – 0.11 −0.01 0.0
PTH 0.30a 0.29a 0.11 – 0.09 0.1
25(OH)D 0.04 −0.01 −0.01 0.09 – 0.2
aCLIgM 0.15 0.05 0.07 0.10 0.20a – 
aCLIgG 0.11 0.06 0.02 −0.04 0.15 0.1
Anti-dsDNA 0.02 0.06 0.16 −0.02 0.07 0.1
Anti-Nucleosome −0.04 −0.16 0.18 −0.08 0.05 0.0
SLE duration 0.12 0.12 0.15 0.09 −0.04 −0.0
Age 0.23 0.21 0.18 0.11 0.06 −0.0
a p < 0.05 according to Kendall  rank correlation coefﬁcient.(p = 0.001) and those aged >45 (p < 0.001). The results are shown
in Fig. 1.
Measurements in the warm and cold seasons did
not reveal any signiﬁcant difference in levels of PINP
(38.58 ± 27.98 ng/mL vs.  51.39 ± 42.17 ng/mL, respectively), OC
(16.49 ± 13.18 vs.  17.59 ± 10.51 ng/mL) or CTX (0.26 ± 0.22 vs.
0.27 ± 0.17 ng/mL) in SLE patients. In addition, no signiﬁcant
difference between warm and cold was found in the SLE sub-
group aged <45 for PINP (26.86 ± 11.89 vs. 56.6 ± 57 ng/mL),
OC (11.31 ± 3.79 vs.  18.03 ± 11.6 ng/mL) or CTX (0.17 ± 0.07
vs. 0.23 ± 0.11 ng/mL), nor in those aged >45 with PINP
(51.58 ± 35.21 vs.  46.98 ± 25.57 ng/mL), OC (22.23 ± 17.44 vs.
17.21 ± 9.96 ng/mL), and CTX (0.36 ± 0.29 vs.  0.31 ± 0.21 ng/mL).
No signiﬁcant difference was revealed between SLE
patients not given steroid treatment and those treated within
the previous 6 months with glucocorticoids at a dosage ≥5 mg
prednisolone daily, or equivalent, with regard to levels of
PINP (47.97 ± 45.52 vs.  41.72 ± 17.72 ng/mL, respectively), OC
(17.43 ± 13.86 vs. 16.36 ± 7.94 ng/mL), and CTX (0.27 ± 0.22 vs.
0.29 ± 0.13 ng/mL). Similarly, no relationship was observed in
those aged <45: PINP (45.53 ± 54.72 vs.  36.67 ± 18.78 ng/mL);
 aCL, anti-DNA and aNuc antibodies obtained in patients
IgM aCL IgG Anti-dsDNA Anti-Nuc SLE duration Age
5 0.11 0.02 −0.04 0.12 0.23a
5 0.06 0.06 0.12 0.21
7 0.02 0.16 0.18 0.15 0.18
0 −0.04 −0.02 −0.08 0.09 0.11
0a 0.15 0.07 0.05 −0.04 0.06
0.14 0.19 0.09 −0.05 −0.09
4 – 0.30a 0.03 0.24 0.10
9 0.30a – 0.43a 0.16 −0.03
9 0.03 0.43a – 0.12 −0.12
5 0.24 0.16 0.12 – 0.31a
9 0.10 −0.03 −0.12 0.31a –







































Fig. 1 – Increased outcomes of procollagen type I N
propeptide were  found signiﬁcantly more  frequently in all
systemic lupus erythematosus patients both in those aged



































dochran’s Q test). Results are displayed as percentage.
C (14.83 ± 10.58 vs.  14.23 ± 7.62 ng/mL); CTX (0.19 ± 0.11 vs.
.2 ± 0.06 ng/mL); nor in those aged >45: PINP (50.41 ± 36.18 vs.
8.79 ± 15.08 ng/mL); OC (20.03 ± 15.55 vs.  19.35 ± 8.21 ng/mL);
r CTX (0.35 ± 0.29 vs.  0.4 ± 0.1 ng/mL).
iscussion
espite the fact that serum PINP and CTX were recommended
n 2011 to be included in all future studies of osteoporotic
racture risk or treatment as reference markers of bone resorp-
ion and formation, there is a lack of studies addressing their
ole in SLE.1 Three studies addressing BTMs in SLE have so
ar been conducted.10–12 However, most of the investigated
TMs are not included in the IOF–IFCC recommendations,
uch as procollagen type I C propeptide (PICP), OC, alka-
ine phosphatase, carboxy-terminal cross-linking telopeptide
f type I collagen (ICTP), and deoxypyridoline excretion.10–12
orczowska et al. report a signiﬁcant increase of CTX in
LE patients, and Bhattoa et al. note a signiﬁcant decrease
n CTX levels between baseline and all subsequent visits
fter one-year transdermal estrogen replacement therapy
n 15 osteopenic postmenopausal SLE patients.11,12 Due to
parse evidence, it is not possible to perform any meta-
nalyses of literature data or draw any convincing conclusions
f their feasibility in lupus. However, an understanding of
TMs should be rooted in the knowledge of the roles played
y them in bone metabolism and the clinical picture of
LE.13,14
An imbalance in bone turnover results in changes in bone
tructure, strength and mass.13,14 Bone mass can be eas-
ly measured by DXA, in contrast to bone structure and
trength, which are difﬁcult to assess in vivo.13,14 BTMs rep-
esent a promising tool in the diagnosis of imbalances in
one turnover measurement.13,14 However, international ref-
rence standards of measurements are required, as reference
anges are not universally deﬁned, and in addition, it is
ifﬁcult to determine precise thresholds or cut-off values 5;5 5(2):133–139 137
for practical use in individual patients.1,14 In our study, the
reference ranges according to age given by the manufacturer
were employed. We have found positive correlations among
the levels of all three BTMs, with the strongest correlation
between PINP and OC; PTH was also found to correlate with
PINP and OC, and age correlated with PINP. Of all the BTMs
tested, PINP, a bone formation marker, was the one most
frequently found to increase. The observed increase in PINP
level in relation to age seems to stand in sharp contrast to
the fact that PINP is a marker of bone formation, although
it is important to remember that PINP provides information
regarding the rate of bone remodeling for the entire skeleton.15
Since a molecule of PINP is enzymatically cleaved off and
secreted into the extracellular space after synthesis of pro-
collagen by osteoblasts, PINP level quantitatively reﬂects the
amounts of newly synthesized collagen.13 However, as only
the simultaneous formation and resorption of bone deter-
mines the rate of bone remodeling at one point in time in vivo,
the elevation of serum PINP in SLE appears to reﬂect the con-
tinuous process of bone formation intended to counter bone
loss.
It may be speculated that PINP level should be decreased
in SLE as a result of glucocorticoid treatment. Baker-LePain
et al. report that serum OC, another bone formation marker,
is negatively correlated with glucocorticoid dose in childhood-
onset systemic lupus.16 Accordingly, Uaratanawong et al. note
that BMD measurements were found to be signiﬁcantly lower
in premenopausal SLE patients who had corticosteroid treat-
ment than those who had not.17 They also identiﬁed a negative
correlation between BMD and corticosteroid therapy, but not
with disease activity.17 In pre-menopausal Mexican women
with SLE, chronic disease damage, low body mass index,
and cumulative corticosteroid dose were found to be risk
factors for low BMD.18 On the other hand, Bhattoa et al.
found that bone mass in men  with SLE was not decreased
despite having undergone corticosteroid therapy, and bio-
chemical markers of bone turnover were within the reference
range.12 In accordance with the study of Bhattoa et al. our
present comparison of PINP with respect to age and gluco-
corticoid use within previous 6 months did not reveal any
signiﬁcant difference in female patients. However, our group
of SLE patients was small and only Caucasian females were
enrolled in the study protocol. The present study also assesses
relationships with glucocorticoid treatment according to a
dichotomic, weak variable: no treatment or any treatment
in the preceding 6 months with prednisolone or equivalent
at a dosage of ≥5 mg  daily. Thus, it is difﬁcult to univocally
state that PINP level in SLE is not related to glucocorti-
coid treatment and studies on larger group of patients are
required.
Nevertheless, the key limitation of our study is the lack
of BMD  measurement. As a result, it could not be veriﬁed
whether the subjects who did not report osteoporosis had
PINP and CTX within normal limits, or whether they were ele-
vated due to a subclinical manifestation of the bone disorder.
By ﬁnding a positive correlation between PINP and PTH and
between PINP and the age of SLE patients, it may be specu-
lated that the elevation of PINP observed in SLE is likely to
be connected with sex steroid deﬁciency and physiological
secondary hyperparathyroidism. However, the levels of sex
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hormones were not assessed and it was impossible to con-
ﬁrm this hypothesis. On the other hand, one may also use
BTMs in assessing the impact of new treatment regimens on
bone metabolism in lupus patients. A recent study by Mendoza
Pinto et al. conducted on 30 patients with SLE found that a one-
year course of treatment with rituximab, surprisingly, resulted
in lower BMD  at both femoral neck and lumbar spine, com-
pared with patients without such therapy.18 However, PINP
and CTX analyses were not performed.
The present study has several limitations which must be
emphasized. Firstly, the number of patients included in the
study was relatively low, and studied individuals were only
female Caucasians with SLE in remission. The main variables
in the assessment of lupus activity were the level of anti-
dsDNA, aNuc and aCL antibodies, which were found not to
correlate with BTMs. Interestingly, Sangle et al. found that
atraumatic metatarsal stress fractures may occur in SLE, par-
ticularly in association with antiphospholipid syndrome.5 Our
results conﬁrm those of Uaratanawong et al. who did not
reveal any correlation between BMD  and disease activity.17
Surprisingly, in childhood-onset SLE, disease activity was
found to be a negative predictor of bone resorption, suggesting
that lupus disease activity is not the primary factor contribut-
ing to the bone deﬁcits.16 Secondly, as mentioned before, BMD
was not performed, which defeats any attempts to estimate
the risk of bone fracture in relation to BTMs. Such algorithms
should also be assessed and further validated in male and
non-Caucasian populations of SLE patients. Finally, our study
was performed at one point in time. With no doubt, follow-
up assessment and longitudinal observation would make a
valuable contribution to the understanding of the rate of bone
metabolism and risk of fracture in the clinical course of SLE.
However, the key strength of our study is that it employs
markers of both bone formation and resorption recommended
by the IOF–IFCC, thus making results more  comparable and
reproducible and leading to meta-analyses of future studies
conducted on larger populations of SLE patients from different
sites.
Several clinical conclusions can be drawn from this study.
First of all, the increased levels of BTMs observed in SLE appear
to be associated with an age-related pattern of bone remodel-
ing. Of all BTMs, increased PINP is expected to be the most
frequently observed. Efforts aimed at a better diagnosis of
bone disturbances using an assessment of bone turnover in
accordance with international reference standards, in addi-
tion to BMD  assessment, need to be included in the diagnostic
approach to SLE patients.
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